The drug is intended to treat adults with advanced or metastatic breast cancer that has progressed despite prior treatment. Verzenio may be used in combination with the endocrine therapy, fulvestrant, or as a stand-alone treatment.
The drug will cost $10,948 a month before any discounts or rebates, according to Reuters. Eli Lilly will offer a special savings card program, in which commercially insured patients can receive the first three months of therapy free, and then pay a maximum of $10 per month for up to a year.
Eli Lilly plans to launch the drug by the end of October.
More articles on supply chain:
AmerisourceBergen fined $260M over cancer drug packaging: 4 things to know
Millennials least likely to comply with recall notices, study finds
A proactive approach to drug shortages: 6 strategies from Advocate Health Care’s director of central service pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
